Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Abstract
loading...
About
In The Last Decade
doi.org/10.1021/jm400487c →Countries where authors are citing Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
This map shows the geographic impact of Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development more than expected).
Fields of papers citing Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
This network shows the impact of Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1021/jm400487c.